Evidence map›Paper›PMID 40160875›Full record

ArticleInternational cancer conference journal2025

Primary adenocarcinoma of the lacrimal sac with 5-year recurrence-free survival after radiation therapy alone: a case report.

Daichi Takizawa, Kayoko Ohnishi, Kentaro Hiratsuka, Ryota Matsuoka, Keiichiro Baba, Masatoshi Nakamura, Takashi Iizumi, Kiyotaka Suzuki, Masashi Mizumoto, Hideyuki Sakurai

Abstract read
In one paragraph

Article in International cancer conference journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daichi TakizawaDepartment of Radiation Oncology, Hitachi General Hospital, 2-1-1 Jonantyo, Hitachi, Ibaraki 317-0077 Japan.ORCID 0000-0003-3480-7075
Kayoko OhnishiDepartment of Radiology, School of Medicine, International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba 286-8686 Japan.
Kentaro HiratsukaDepartment of Ophthalmology, Hitachi General Hospital, 2-1-1 Jonantyo, Hitachi, Ibaraki 317-0077 Japan.
Ryota MatsuokaDepartment of Pathology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8577 Japan.
Keiichiro BabaDepartment of Radiation Oncology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8577 Japan.
Masatoshi NakamuraDepartment of Radiation Oncology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8577 Japan.
Takashi IizumiDepartment of Radiation Oncology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8577 Japan.
Kiyotaka SuzukiDepartment of Radiation Therapy, Hitachi General Hospital, 2-1-1 Jonantyo, Hitachi, Ibaraki 317-0077 Japan.
Masashi MizumotoDepartment of Radiation Oncology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8577 Japan.
Hideyuki SakuraiDepartment of Radiation Oncology, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8577 Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lacrimal sac tumors are rare, with approximately 800 cases reported worldwide; primary adenocarcinoma of the lacrimal sac is particularly rare. Although there is no established treatment strategy, surgical removal is generally performed. However, complete removal often requires extensive resection, including orbital exenteration and lateral rhinoplasty, which is highly invasive and creates significant cosmetic issues. Here, we report our experience with a 72-year-old woman with primary adenocarcinoma of the lacrimal sac with ethmoid bone invasion. She refused surgery and was treated with radiation therapy alone, totaling 70 Gy in 35 fractions. This is the first report of a patient with primary adenocarcinoma of the lacrimal sac who survived for 5 years without recurrence after radiation therapy alone. She experienced late radiation-related complications: the affected eye developed grade-3 retinopathy according to the common terminology criteria for adverse events, version 5.0, and secondary neovascular glaucoma. Cataract and vitreous surgery with retinal photocoagulation were performed. Her cosmetic appearance was maintained after all treatments were completed. Radiation therapy may be an effective treatment for primary adenocarcinoma of the lacrimal sac for patients who either refuse surgery or in whom surgery is not feasible.

Indexed as

AgedFacial neoplasmsLacrimal sacRadiation therapy

Identifiers

PMID40160875
PMCPMC11950477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.